Brainstorm Cell (BCLI)

$0.84 -0.33 (-28.21%)
Market Cap 11.51M
Revenue (ttm) 0.00
Net Income (ttm) -11.62M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio -0.16
Volume 819,600
Avg Vol 1,676,626
Day's Range N/A - N/A
Shares Out 9.84M
Stochastic %K 34%
Beta 0.22
Analysts Strong Sell
Price Target $7.50

Company Profile

Brainstorm Cell Therapeutics Inc. a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company's NurOwn proprietary cell therapy platform that leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance...

Industry: Biotechnology
Sector: Healthcare
Phone: 201 488 0460
Address:
1325 Avenue of Americas, 28th Floor, New York, United States
Pipemajors82
Pipemajors82 Apr. 6 at 9:15 PM
$BCLI https://www.facebook.com/share/1BGoLDgCaF/
0 · Reply
rosiesc
rosiesc Apr. 6 at 9:09 PM
$AMLX $BCLI $LABD $PFE $RGC
0 · Reply
ALSCellTherapy
ALSCellTherapy Apr. 6 at 8:07 PM
$BCLI
0 · Reply
MetalFistSlip
MetalFistSlip Apr. 6 at 8:04 PM
$BCLI $AMLX $LABD $RGC $PFE Please ignore this post if you aren’t familiar with the name Poppy… This sick account Lion0fWallSt has been using these innocent womens pictures in his bear posts pretending it’s them… I feel terrible to have been making fun of them… I got into contact with the real Poppy and she’s just some poor girl who didn’t know any of this was going on. Report this sicko. And remember this fraud. To the women we’ve been making fun of, I apologize.
0 · Reply
AshvsEvilDead
AshvsEvilDead Apr. 6 at 7:42 PM
$BCLI 310 day avg review time in 2025. We are at ~280 for the citizens petition.
0 · Reply
HUMBL4Now
HUMBL4Now Apr. 6 at 2:41 PM
$BCLI what’s goin on with clene today…big rise
0 · Reply
steven1x
steven1x Apr. 4 at 1:44 PM
$BCLI most interesting but not directly related https://g.co/gemini/share/a4a167dbe07c
2 · Reply
DoctorJT
DoctorJT Apr. 3 at 2:04 AM
$BCLI I do not love this post from Michelle on NurOwn, in relation to hope for an expedient approval. I suspect she is probably in the know, more than most, RE: the status of the CP, and the fact she is making such a post on X, in my lay opinion, wouldn’t seem to bode well for a favorable ruling of the CP being on the near-term horizon. https://x.com/avoice4als/status/2038984627726246144?s=46
3 · Reply
ALSCellTherapy
ALSCellTherapy Apr. 2 at 7:07 PM
$BCLI Humble they are accumulating shares.
1 · Reply
HUMBL4Now
HUMBL4Now Apr. 2 at 2:43 PM
$BCLI uh oh….dropping today
0 · Reply
Latest News on BCLI
No data available.
Pipemajors82
Pipemajors82 Apr. 6 at 9:15 PM
$BCLI https://www.facebook.com/share/1BGoLDgCaF/
0 · Reply
rosiesc
rosiesc Apr. 6 at 9:09 PM
$AMLX $BCLI $LABD $PFE $RGC
0 · Reply
ALSCellTherapy
ALSCellTherapy Apr. 6 at 8:07 PM
$BCLI
0 · Reply
MetalFistSlip
MetalFistSlip Apr. 6 at 8:04 PM
$BCLI $AMLX $LABD $RGC $PFE Please ignore this post if you aren’t familiar with the name Poppy… This sick account Lion0fWallSt has been using these innocent womens pictures in his bear posts pretending it’s them… I feel terrible to have been making fun of them… I got into contact with the real Poppy and she’s just some poor girl who didn’t know any of this was going on. Report this sicko. And remember this fraud. To the women we’ve been making fun of, I apologize.
0 · Reply
AshvsEvilDead
AshvsEvilDead Apr. 6 at 7:42 PM
$BCLI 310 day avg review time in 2025. We are at ~280 for the citizens petition.
0 · Reply
HUMBL4Now
HUMBL4Now Apr. 6 at 2:41 PM
$BCLI what’s goin on with clene today…big rise
0 · Reply
steven1x
steven1x Apr. 4 at 1:44 PM
$BCLI most interesting but not directly related https://g.co/gemini/share/a4a167dbe07c
2 · Reply
DoctorJT
DoctorJT Apr. 3 at 2:04 AM
$BCLI I do not love this post from Michelle on NurOwn, in relation to hope for an expedient approval. I suspect she is probably in the know, more than most, RE: the status of the CP, and the fact she is making such a post on X, in my lay opinion, wouldn’t seem to bode well for a favorable ruling of the CP being on the near-term horizon. https://x.com/avoice4als/status/2038984627726246144?s=46
3 · Reply
ALSCellTherapy
ALSCellTherapy Apr. 2 at 7:07 PM
$BCLI Humble they are accumulating shares.
1 · Reply
HUMBL4Now
HUMBL4Now Apr. 2 at 2:43 PM
$BCLI uh oh….dropping today
0 · Reply
ALSCellTherapy
ALSCellTherapy Apr. 1 at 8:31 PM
$BCLI $0.9498
1 · Reply
AshvsEvilDead
AshvsEvilDead Apr. 1 at 7:35 PM
$BCLI This seems like such a sleeper. Company DTR yet have a clear path for a confirmatory trial following approval off the CP. I mean sure there’s risk with the FDA but they have effectively de-risked every other area with the FDA. The only big risk is a significant raise required for the trial assuming FDA says no, but man that just seems like 180 from where they are aligned with approvals right now. It’s essentially totality vs substantial/rigor. I guess actions speak louder than words but this FDA has been trying to separate itself from substantial/rigor in rare disease with unmet need.
1 · Reply
ALSCellTherapy
ALSCellTherapy Apr. 1 at 7:10 PM
$BCLI
0 · Reply
Knuckles30
Knuckles30 Apr. 1 at 2:43 PM
$BCLI WILL ALS THERAPY PLEASE STFU EVERYONE IS SO TIRED OF UR SAME OLD BULLSHIT…U R CHIAMS CHEERLEADER.. I WANT TO KNOW IF THIS COMPANY IS READY DAY 1 IF CP IS APPROVED. DOUBT IT WITH THIS COMPANIES LEADERSHIP… .. ALS PLEASE STOP POSTING YOU ARE A FIRST CLASS HEMROID
3 · Reply
80xEddiep
80xEddiep Apr. 1 at 10:42 AM
$BCLI why is the chart stuck on this one?
1 · Reply
ALSCellTherapy
ALSCellTherapy Apr. 1 at 2:50 AM
$BCLI Get your shares while you can!!!
1 · Reply
ALSCellTherapy
ALSCellTherapy Apr. 1 at 2:49 AM
$BCLI I am telling you this biotech has the goods and is the real deal! A goldmine! And still only 95 cents...
0 · Reply
ALSCellTherapy
ALSCellTherapy Apr. 1 at 1:28 AM
$BCLI Form 10-K Intellectual Property A key element of our strategy is to establish and maintain a broad intellectual property portfolio to protect our proprietary technologies and products. BrainStorm holds approximately 30 granted patents, as well as pending applications, across the United States, Europe, and other key global markets, including the Far East and South America. Along with our existing intellectual property protection for NurOwn® (MSC-NTF), we have been expanding our portfolio in recent years to cover exosome-based technologies, with several key developments.
0 · Reply
ALSCellTherapy
ALSCellTherapy Apr. 1 at 1:26 AM
$BCLI Paragraph 2 and 3 With NurOwn® as our foundation in stem cell-based therapeutics, our next strategic platform is exosome-based technology. This platform expands our pipeline beyond autologous cellular therapy, harnessing the regenerative and immunomodulatory properties of exosomes derived from NurOwn® (MSC-NTF cells). Notably, exosomes have the potential to serve as an allogeneic, off-the-shelf therapeutic product. We have generated compelling preclinical data demonstrating the potential of our exosome-based technology across multiple areas of unmet medical need. Our research continues to explore new therapeutic applications, leveraging the unique ability of exosomes to deliver bioactive molecules, modulate inflammation, and promote tissue repair. This strategic expansion positions BrainStorm at the forefront of exosome-based innovation, complementing our expertise in cellular therapy and broadening our opportunities for clinical translation.
0 · Reply
ALSCellTherapy
ALSCellTherapy Apr. 1 at 1:22 AM
$BCLI Form 10-K Company Business Strategy Paragraph 1 Our overarching strategy is to develop, obtain regulatory approval for, and commercialize our proprietary NurOwn® and Exosome-based products through a methodical, data-driven approach to research, development, and clinical trials. Our clinical programs are subject to the regulatory authority of global regulatory authorities, including the U.S. Food and Drug Administration (FDA). Our highest priority is securing regulatory approval for NurOwn® in ALS, including the potential submission of a Biologics License Application (BLA) to the FDA following the successful completion of our Phase 3b clinical trial, while simultaneously advancing its clinical development in Progressive Multiple Sclerosis (PMS). We are also strategically expanding our Exosome-based platform technology to explore new therapeutic applications.
0 · Reply
HUMBL4Now
HUMBL4Now Apr. 1 at 1:01 AM
$BCLI another disappointing update wkth absolutely nothing new. Based on their financials, the $2 million is just gonna keep paying salaries for the next 12 months and they still have no plan and zero ambition.
1 · Reply
DoctorJT
DoctorJT Mar. 31 at 11:23 PM
$BCLI on a brief skim of today’s 10-K, I sadly didn’t see anything at all about the CP.
2 · Reply